Skip to Content
menu

Our Pipeline

We are building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.

Programs
In Vivo CRISPR is the therapy
Ex Vivo CRISPR creates the therapy
Program
Research and
Preclinical
Early-Stage
Clinical
Late-Stage
Clinical
Partners
Genetic Diseases
NTLA-2001 (nexiguran ziclumeran**) Transthyretin (ATTR)
Amyloidosis
Late-Stage
Clinical
NTLA-2002 Hereditary
Angioedema
Late-Stage
Clinical
NTLA-3001 AATD-Lung
Disease
Research and
Preclinical
Hemophilia A / B***
Research and
Preclinical
Research Programs
Research
Research Programs
Research
  • *
Immuno-Oncology / Autoimmune Disease
Research Programs
Research
  • *
  • AATD: alpha-1 antitrypsin deficiency
  • Lead refers to lead development and commercial party
  • * Intellia is advancing both wholly-owned and partnered programs.
  • ** NTLA-2001 is now known as nexiguran ziclumeran (nex-z)
  • *** Hemophilia A program is in the research stage. Hemophilia B is being advanced by Regeneron. Intellia is eligible for milestones and royalties.

Download

Our pipeline

Learn more

About Intellia’s full-spectrum approach